A Case of Paroxysmal Nocturnal Hemoglobinuria (PNH) in an Obstetric Patient: A South African Perspective
Abstract
Paroxysmal Nocturnal Hemoglobinuria (PNH) originates from an acquired genetic defect in a multipotent hematopoietic stem cell that becomes stem-cell-like in its ability to survive, expand, and self-renew. PNH is a rare condition characterized by intravascular hemolysis. PNH can arise anew or in the setting of an underlying bone marrow disorder such as aplastic anemia (AA), myelodysplastic syndrome (MDS), or primary myelofibrosis (PMF).
This case presentation documents the challenging diagnosis of PNH in the obstetric setting, in which other possible causes for a hemolytic anemia could be considered. We discuss the management of a pregnancy in the presence of PNH in a low-to-middle income setting.
References
Brodsky RA. Pathogenesis of paroxysmal nocturnal hemoglobinuria. 2017. Available at https://www.uptodate.com/contents/pathogenesis-of-paroxysmal-nocturnal-hemoglobinuria (last accessed January 2019)
Lauritsch-Hernandez LS, Kraehenmann F, Balabanov S, et al. Eculizumab application during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: A case report with review of the literature. Clin Case Rep 2018; 6: 1582-7; https://doi.org/10.1002/ccr3.1634
Miyasaka N, Miura O, Kawaguchi T, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol 2016; 103: 703-12; https://doi.org/10.1007/s12185-016-1946-x
Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 2017; 3: 17028; https://doi.org/10.1038/nrdp.2017.28
Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in pregnant patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med 2015; 373: 1032-9; https://doi.org/10.1056/NEJMoa1502950
Bastos JMC, Pinheiro PL, Rocha LC, et al. Therapeutic challenges in pregnant women with paroxysmal nocturnal hemoglobinuria: A case report. Medicine (Baltimore) 2018; 97: e12155; https://doi.org/10.1097/MD.0000000000012155
AA.VV. FDA Pregnancy Categories. Available at https://www.drugs.com/pregnancy-categories.html (last accessed January 2019)
Dinerstein C. Why Is Soliris the Most Expensive Drug In The US? American Council in Science and Health. May 27, 2017. Available at https://www.acsh.org/news/2017/05/27/why-soliris-most-expensive-drug-us-11333 (last accessed January 2019)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
HTML: 175 views
PDF: 131 views
